Efficacy Analysis and Influencing Factors of HBsAg Response in Chronic Hepatitis B Patients Treated with Nucleoside Analogues and Pegylated Interferon Sequential Therapy with High HBsAg Levels
| Author | Jingdan Chen | en |
| Author | Shangkun Lai | en |
| Author | Mijia Zheng | en |
| Issued Date | 2025-12-31 | en |
| Abstract | Background: Chronic hepatitis B (CHB) patients with high hepatitis B surface antigen [hepatitis B surface antigen (HBsAg), > 1500 IU/mL] during nucleos(t)ide analogs (NAs) treatment are considered a "non-optimal population" with poor responses. Sequential pegylated interferon (PEG-IFN) therapy can reduce HBsAg levels, but individual responses vary. Objectives: The present study aimed to explore factors influencing HBsAg response in this population. Methods: This retrospective, single-center study included 85 CHB patients who had received NAs for at least one year, had HBsAg levels > 1500 IU/mL, and were HBV DNA-negative. Patients were divided into two groups: The study group (n = 35) received PEG-IFN sequentially combined with NAs, while the control group (n = 50) continued on NAs monotherapy. The HBsAg decline rates at weeks 12, 24, and 48 were compared between the two groups. A generalized estimating equation (GEE) model was used to analyze factors associated with HBsAg reduction. Results: The median HBsAg decline rates at weeks 12, 24, and 48 in the study group were 43.92%, 63.68%, and 84.55%, respectively, significantly greater than those in the control group (2.86%, 5.95%, and 11.02%, respectively; all P < 0.001). At week 48, the clinical response rate was 22.86% in the study group versus 0% in the control group (P < 0.001). The GEE analysis showed that treatment group, time, and their interaction significantly influenced HBsAg dynamics (all P < 0.05). The odds ratio for HBsAg reduction in the study group was 2.673 (95% CI: 1.815 - 3.937). Conclusions: Sequential PEG-IFN combined with NAs significantly improves HBsAg reduction and clinical response rates in CHB patients with high baseline HBsAg, with efficacy increasing over time, supporting its role in optimizing treatment for this population. | en |
| DOI | https://doi.org/10.5812/hepatmon-165180 | en |
| Keyword | Chronic Hepatitis B | en |
| Keyword | High HBsAg Levels | en |
| Keyword | Pegylated Interferon | en |
| Keyword | Sequential Therapy | en |
| Keyword | Nucleos(t)ide Analogs | en |
| Publisher | Brieflands | en |
| Title | Efficacy Analysis and Influencing Factors of HBsAg Response in Chronic Hepatitis B Patients Treated with Nucleoside Analogues and Pegylated Interferon Sequential Therapy with High HBsAg Levels | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-25-1-165180-publish-pdf.pdf
- Size:
- 375.97 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF